4000-520-616
欢迎来到免疫在线!(蚂蚁淘生物旗下平台)  请登录 |  免费注册 |  询价篮
主营:主营:医疗设备、医疗耗材、实验仪器、抗体、试剂、诊断等产品
咨询热线电话
4000-520-616
当前位置: 首页 > 产品中心 > peptide > BD Biosciences/CD103 FITC/CD22 PE/CD20 PerCP-Cy™5.5/333174
商品详细BD Biosciences/CD103 FITC/CD22 PE/CD20 PerCP-Cy™5.5/333174
BD Biosciences/CD103 FITC/CD22 PE/CD20 PerCP-Cy™5.5/333174
BD Biosciences/CD103 FITC/CD22 PE/CD20 PerCP-Cy™5.5/333174
商品编号: 333174
品牌: bdbiosciences
市场价: ¥0.00
美元价: 0.00
产地: 美国(厂家直采)
公司:
产品分类: 多肽合成
公司分类: peptide
联系Q Q: 3392242852
电话号码: 4000-520-616
电子邮箱: info@ebiomall.com
商品介绍
Product DetailsRecommended AssayReferences

Description

BD Oncomark™ CD103 FITC/CD22 PE/CD20 PerCP-Cy5.5 is intended for in vitro flow cytometric immunophenotyping of normal and abnormal subsets of B lymphocytes. The reagents detect expression of the CD103, CD22, and CD20 antigens. These antigens are highly expressed in the abnormal cells of hairy-cell leukemia. A subset of normal B cells expressing CD103 has been identified in peripheral blood. CD103/CD22/CD20 assays are used in the diagnosis of hematologic disorders.

Contents

SpecificityCloneFormatIsotypeEntrez Gene ID
CD103 (Integrin αIEL chain)Ber-ACT8FITCIgG1, κ3682
CD22S-HCL-1 (also known as S-HCL1)PEIgG2b, κ933
CD20L27PerCP-Cy™5.5IgG1, κ931
Preparation and Storage

The antibody reagent is stable until the expiration date shown on the label when stored at 2° to 8°C. Do not use after the expiration date. Do not freeze the reagent or expose it to direct light during storage or incubation with cells. Keep the outside of the reagent vial dry.

Do not use the reagent if you observe any change in appearance. Precipitation or discoloration indicates instability or deterioration.

  1. Protection of Laboratory Workers from Occupationally Acquired Infections–Second Edition; Approved Guideline. Villanova, PA: National Committee for Clinical Laboratory Standards; 2001. NCCLS document M29-A2.

  2. Borowitz M, Bonsvaros A, Brynes R, et al. Monoclonal antibody phenotyping of B cell non-Hodgkins lymphoma: The Southeastern Cancer Study Group experience. Am J Pathol. 1985;121:514-521.

  3. Braylan RC, Benson NA, Iturraspe J. Analysis of lymphomas by flow cytometry: current and emerging strategies. Ann N Y Acad Sci. 1993;677:364-378.

  4. Centers for Disease Control. Update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in health-care settings. MMWR. 1988;37:377-388.

  5. Cepek K, Wong D, Brenner M, Springer T. CD103 (αE) cluster report. In: Schlossman S, Boumsell L, Gilks W, et al, eds Leucocyte Typing V: White Cell Differentiation Antigens. 1995;2:1666-1667.

  6. Dörken B, Möller P, Pezzutto A, Schwartz-Albiez R, Moldenhauer G. B-cell antigens: CD20. In: Knapp W, Dörken B, Gilks WR, et al, eds. Leucocyte Typing IV: White Cell Differentiation Antigens. 1989:46-48.

  7. Hoffkes HG, Schmidtke G, Uppenkamp M, Schmucker U. Multiparametric immunophenotyping of B cells in peripheral blood of healthy adults by flow cytometry. Clin Diagn Lab Immunol. 1996;3:30-36.

  8. Hultin LE, Hausner MA, Hultin PM, Giorgi JV. CD20 (Pan-B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes. Cytometry. 1993;14:196-204.

  9. Jackson AL, Warner NL. Preparation, staining, and analysis by flow cytometry of peripheral blood leukocytes. In: Rose NR, Friedman H, Fahey JL, eds. Manual of Clinical Laboratory Immunology. 3rd ed. Washington, DC: American Society for Microbiology; 1986:226-235.

  10. Kruschwitz M, Fritzsche G, Schwarting R, et al. Ber-ACT8: new monoclonal antibody to the mucosa lymphocyte antigen. J Clin Pathol. 1991;44:636-645.

  11. Letwin BW, Wallace PK, Muirhead KA, Hensler GL, Kashatus WH, Horan PK. An improved clonal excess assay using flow cytometry and B-cell gating. Blood. 1990;75:1178-1185.

  12. Loken MR, Shah V, Hollander Z, Civin C. Flow cytometric analysis of normal B lymphoid development. Pathol Immunopathol Res. 1988;7:357-370.

  13. Loken MR, Shah VO, Dattilio KL, Civin CI. Flow cytometric analysis of human bone marrow. II. Normal B-lymphocyte development. Blood. 1987;70:1316-1324.

  14. Mason D, Stein H, Gerdes J, et al. Monoclonal Anti-CD22 (p135) antibodies for the detection of normal and neoplastic B lymphoid cells. Blood. 1987;69:836.

  15. Micklem KJ, Dong Y, Willis A, et al. HML-1 antigen on mucosa-associated T cells, activated cells, and hairy leukemic cells is a new integrin containing the Β7 subunit. Am J Pathol. 1996;3:30-36.

  16. Nadler LM. B Cell/Leukemia Panel Workshop: summary and comments. In: Reinherz EL, Haynes BF, Nadler LM, Bernstein ID, eds. Leukocyte Typing II: Human B Lymphocytes. 1986;2:3-43.

  17. Parker CM, Cepek KL, Russell GJ, et al. A family of Β7 integrins on human mucosal lymphocytes. Proc Natl Acad Sci USA. 1992;89:1924-1928.

  18. Rothe G, Schmitz G. Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies. Leukemia. 1996;10:877-895.

  19. Schwarting R, Stein H, Wang CY. The monoclonal antibodies Anti-S-HCL-1 and Anti-S-HCL-3 allow the diagnosis of hairy cell leukemia. Blood. 1985;65:974-983.

  20. Stelzer GT, Marti G, Hurley A, McCoy P, Jr., Lovett EJ, Schwartz A. US-Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: standardization and validation of laboratory procedures. Cytometry. 1997;30:214-230.

  21. Tanaka T, Goda K, Takeuchi E, Miyasaka M. CD103 Workshop Panel report. In: Kishimoto T, Kikutani H, von dem Borne AEGK, eds. Kikutani H, von dem Borne AEGK, eds. Leucocyte Typing VI: White Cell Differentiation Antigens. New York, NY; Garland Publishing, Inc.; 1997:430-432.

  22. Terstappen LWMM, Johnsen S, Segers-Nolten IMJ, Loken MR. Identification and characterization of plasma cells in normal human bone marrow by high resolution flow cytometry. Blood. 1990;76:1739-1747.

  23. Weinberg DS, Pinkus GS, Ault KA. Cytofluorometric detection of B cell clonal excess: a new approach to the diagnosis of B cell lymphoma. Blood. 1984;63:1080-1087.

品牌介绍
BD是世界上最大的生产和销售医疗设备、医疗系统和试剂的医疗技术公司之一。致力于提高全世界人类的健康水平。BD专注于改进药物治疗,提高传染性疾病诊断的质量和速度,推进新型药物和疫苗的研究与发现。BD公司具有强大的研发能力和世界上最棘手的多种疾病进行斗争的能力。公司于1897年在纽约成立,总部位于美国新泽西州的富兰克林湖,业务遍及全球。公司的业务可分为BD医疗、BD诊断、BD生物科学三大类,生产销售包括医用耗材、实验室仪器、抗体、试剂、诊断等产品。公司的服务对象包括医疗机构,生命科学研究所,临床实验室,工业单位和普通大众。BD has state-of-the-art facilities around the globe that provide an environment that enables our highly talented workforce to be the best at their professions. We hire associates who have a passion and commitment to advancing the world of health. We are always seeking great people to join our company on its journey to greatness.BDRat Granulocytes Pure RP-1  500ug550002BDMs Ig Kpa Lgt Chain FITC 187.1  500ug550007BDICC Fixation Buffer 100mL550011BDMs CD210 NALE 1B1.3a 500ug550019BDMs CD51 Pure RMV-7 100ug550026BDMs CD5 APC 53-7.3 100ug550037BDHu CD62E PE-Cy5 68-5H11 100Tst550041BDHu CD95 Pure EOS9.1  100ug550052BDHam IgG2 Kpa ItCl FITC B81-3 250ug550057BDMs Crry/p65 Pure 1F2 100ug550059BDMs IL-4 Recom Protein 10ug550068BDMs IL-2 Recom Protein 20ug550070BDHu IL-6 Recom Protein 10ug550072BDHu MIP-1 Bta PE D21-1351 100ug550082BDMs IgG1 PE A85-1 100ug550084BDHam IgG2 Kpa ItCl PE B81-3 100ug550086BDHu CD142 Pure HTF-1 100ug550254BDHu CD1d PE CD1d42 100Tst550256BDHu CD73 PE AD2 100Tst550258BDHu CD103 FITC Ber-ACT8 100Tst550260BDMs CD11c APC HL3 100ug550268BDMs CD72b/c Aloatg PE JY/93 100ug550270BDRat CD32 Pure D34-485 500ug550272BDRat CD32 NALE D34-485 500ug550274BDMs CD3e IHC Pure 145-2C11 1mL550277BDMs CD4 IHC Pure H129.19 1mL550280BDMs CD8a IHC Pure 53-6.7 1mL
联络我们
服务热线:4000-520-616
(限工作日9:00-18:00)
QQ :1570468124
手机:18915418616